Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01553851 · ClinicalTrials.gov registry record · Phase 2
GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01553851 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 20 participants.
The verdict
NCT01553851, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This phase II trial studies how trametinib effects tumor cells in patients with oral cavity squamous cell carcinoma that can be removed by surgery. Trametinib may shrink the tumor by blocking an enzyme pathway needed for cell growth.
Interventions
- DRUG GSK1120212
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-02 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01553851
The ClinicalTrials.gov registry entry for NCT01553851 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK1120212 is the first listed.
NCT01553851 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01553851 about?
NCT01553851 is a clinical study titled "GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer". This phase II trial studies how trametinib effects tumor cells in patients with oral cavity squamous cell carcinoma that can be removed by surgery. Trametinib may shrink the tumor by blocking an enzyme pathway needed for cell growth.
What is the current status of trial NCT01553851?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2013-02. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01553851?
The interventions under investigation include: GSK1120212 (DRUG).
Who is sponsoring clinical trial NCT01553851?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.